tradingkey.logo

Hims slides after US FDA warns against 'illegal copycat drugs'

ReutersFeb 6, 2026 10:09 AM

Shares of U.S. telehealth firm Hims and Hers Health HIMS.N fall 7.11% to $21.81 premarket

U.S. FDA Commissioner Marty Makary said on Thursday that the regulator would take action against companies that mass-market "illegal copycat drugs" by claiming they are similar to FDA-approved products

HIMS began offering a cheaper $49 compounded version of Novo Nordisk's NOVOb.CO new Wegovy weight-loss pill

In 2025, HIMS shares gained 34.28%

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI